Home LiteratureArticle Details
PMID: 20801068 Published · ppublish English Journal Article Research Support, N.I.H., Intramural

Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy.

Molecular genetics and metabolism ·Vol. 101 ·No. 4 ·2010-12-00 ·Pages 324-31

Raben N, Ralston E, Chien YH, Baum R, Schreiner C, Hwu WL, Zaal KJ, Plotz PH

Abstract

Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase, the enzyme that degrades glycogen in the lysosomes. The disease manifests as a fatal cardiomyopathy and skeletal muscle myopathy in infants; in milder late-onset forms skeletal muscle is the major tissue affected. We have previously demonstrated that autophagic inclusions in muscle are prominent in adult patients and the mouse model. In this study we have evaluated the contribution of the autophagic pathology in infants before and 6 months after enzyme replacement therapy. Single muscle fibers, isolated from muscle biopsies, were stained for autophagosomal and lysosomal markers and analyzed by confocal microscopy. In addition, unstained bundles of fixed muscles were analyzed by second harmonic imaging. Unexpectedly, the autophagic component which is so prominent in juvenile and adult patients was negligible in infants; instead, the overwhelming characteristic was the presence of hugely expanded lysosomes. After 6 months on therapy, however, the autophagic buildup becomes visible as if unmasked by the clearance of glycogen. In most fibers, the two pathologies did not seem to coexist. These data point to the possibility of differences in the pathogenesis of Pompe disease in infants and adults.

MeSH Terms
Adult Autophagy/physiology Child Child, Preschool Enzyme Replacement Therapy Glycogen Storage Disease Type II/drug therapy,enzymology,pathology Humans Infant Infant, Newborn Lysosomes/enzymology,pathology Muscle Fibers, Skeletal/pathology alpha-Glucosidases/deficiency,metabolism,therapeutic use
Chemicals
GAA protein, human alpha-Glucosidases
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Raben Nina
Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892-1820, USA. rabenn@mail.nih.gov
Ralston Evelyn
Chien Yin-Hsiu
Baum Rebecca
Schreiner Cynthia
Hwu Wuh-Liang
Zaal Kristien J M
Plotz Paul H
References (35)
35 references, click to expand
  1. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.
    J Pediatr. 2006 May;148(5):671-676 PMID: 16737883
  2. Autophagy in the pathogenesis of disease.
    Cell. 2008 Jan 11;132(1):27-42 PMID: 18191218
  3. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.
    Pediatrics. 2008 Jul;122(1):e39-45 PMID: 18519449
  4. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.
    Pediatrics. 2003 Aug;112(2):332-40 PMID: 12897283
  5. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease.
    Mol Ther. 2006 Dec;14(6):831-9 PMID: 17008131
  6. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand...
    Autophagy. 2007 Nov-Dec;3(6):546-52 PMID: 17592248
  7. Lysosomal disorders: from storage to cellular damage.
    Biochim Biophys Acta. 2009 Apr;1793(4):684-96 PMID: 19111581
  8. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
    J Neurol. 2010 Jan;257(1):91-7 PMID: 19649685
  9. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation.
    J Cell Sci. 2004 Jun 1;117(Pt 13):2805-12 PMID: 15169837
  10. Regulation mechanisms and signaling pathways of autophagy.
    Annu Rev Genet. 2009;43:67-93 PMID: 19653858
  11. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
    J Child Neurol. 2007 May;22(5):565-73 PMID: 17690063
  12. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Mol Ther. 2005 Jan;11(1):48-56 PMID: 15585405
  13. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease.
    Pediatr Res. 2009 Sep;66(3):329-35 PMID: 19542901
  14. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
    Mol Genet Metab. 2010 Jan;99(1):26-33 PMID: 19775921
  15. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect.
    Hum Mutat. 1998;11(4):306-12 PMID: 9554747
  16. Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II.
    J Neurol. 2008 Jun;255(6):831-8 PMID: 18458862
  17. A randomized study of alglucosidase alfa in late-onset Pompe's disease.
    N Engl J Med. 2010 Apr 15;362(15):1396-406 PMID: 20393176
  18. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.
    Genet Med. 2009 Mar;11(3):210-9 PMID: 19287243
  19. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.
    Neurology. 2007 Jan 9;68(2):99-109 PMID: 17151339
  20. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
    Ann Neurol. 2004 Apr;55(4):495-502 PMID: 15048888
  21. Autophagy fights disease through cellular self-digestion.
    Nature. 2008 Feb 28;451(7182):1069-75 PMID: 18305538
  22. Therapeutic approaches in glycogen storage disease type II/Pompe Disease.
    Neurotherapeutics. 2008 Oct;5(4):569-78 PMID: 19019308
  23. Constitutive autophagy: vital role in clearance of unfavorable proteins in neurons.
    Cell Death Differ. 2007 May;14(5):887-94 PMID: 17332773
  24. The natural course of non-classic Pompe's disease; a review of 225 published cases.
    J Neurol. 2005 Aug;252(8):875-84 PMID: 16133732
  25. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease.
    Ann Neurol. 2006 Apr;59(4):700-8 PMID: 16532490
  26. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.
    Genet Med. 2001 Mar-Apr;3(2):132-8 PMID: 11286229
  27. Pompe disease in infants: improving the prognosis by newborn screening and early treatment.
    Pediatrics. 2009 Dec;124(6):e1116-25 PMID: 19948615
  28. Detection and imaging of non-contractile inclusions and sarcomeric anomalies in skeletal muscle by second harmonic generation combined with two-photon excited fluorescence.
    J Struct Biol. 2008 Jun;162(3):500-8 PMID: 18468456
  29. Enzyme replacement therapy in the mouse model of Pompe disease.
    Mol Genet Metab. 2003 Sep-Oct;80(1-2):159-69 PMID: 14567965
  30. Autophagy revisited: a conversation with Christian de Duve.
    Autophagy. 2008 Aug;4(6):740-3 PMID: 18567941
  31. Monitoring autophagy in lysosomal storage disorders.
    Methods Enzymol. 2009;453:417-49 PMID: 19216919
  32. Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture.
    Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;45(1):23-36 PMID: 6199885
  33. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
    EMBO J. 2000 Nov 1;19(21):5720-8 PMID: 11060023
  34. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.
    J Pediatr. 2006 Jul;149(1):89-97 PMID: 16860134
  35. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease.
    Lab Invest. 2006 Dec;86(12):1208-20 PMID: 17075580
Article Info
Journal
Molecular genetics and metabolism
Abbr.
Mol Genet Metab
ISSN
1096-7206
Published
2010-12-00
Epub
2010-00-07
Pages
324-31
Language
English
Region
United States
NLM ID
9805456
PMCID
PMC2991562
Subset
IM
Grants
Intramural NIH HHS · Z99 AR999999 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com